Novo Holdings’ Post

Novo Holdings, a leading life science investor, has led a $105 million financing in Magenta Medical Ltd., developers of the Elevate System, the world’s smallest heart pump. This funding supports Magenta’s US clinical programs, targeting FDA approval for the Elevate System in patients undergoing high-risk percutaneous coronary interventions (HR-PCI). The Elevate System, designed for mechanical circulatory support (MCS), offers a minimally invasive solution for patients with severe cardiovascular conditions, earning FDA's Breakthrough Device Designation. Eric Snyder from Novo Holdings joins Magenta’s Board of Directors, expressing confidence in the technology's potential to transform patient care. Magenta Medical Ltd.'s CEO Dr. David Israeli welcomes this partnership, emphasizing the alignment with other top MedTech investors to advance their mission. With a pivotal US study on the horizon, Magenta is poised to make significant strides in the MCS field. Click the link below to learn more about the implications of this investment. https://lnkd.in/eaJWNQbz #MetricBio #MedicalInnovation #HeartHealth #MCS #MagentaMedical #NovoHoldings

Retriever Medical 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗿𝗼𝘂𝗻𝗱 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝘁𝗵𝗿𝗼𝗺𝗯𝗲𝗰𝘁𝗼𝗺𝘆 𝘀𝘆𝘀𝘁𝗲𝗺 💰 Retriever Medical is seeking $10M in Series A funding to drive their novel thrombectomy system for treating pulmonary embolism (PE) and deep vein thrombosis (DVT) through FDA clearance and clinical studies. 🔥 They've raised $3.5M to date and are partnering with leaders like Resonetics and Midwest Interventional Systems, Inc. 🩸 Their unique dual-basket, drug-eluting mechanical thrombectomy device paired with aspiration and reinfusion is poised to make a major impact in the rapidly growing venous thromboembolism market. 📈 The venous thromboembolism treatment market has huge potential - with the likes of Inari Medical projecting $575M in revenue this year while only tapping 25% of the available patient population who are currently treated with anticoagulants. #Thrombectomy #MechanicalThrombectomy #Vascular #MedTech

🫀🤝Edwards Lifesciences continues their M&A spree with yet another #structuralheart acquisition, by way of Genesis Medtech Group and their JC Medical, Inc. subsidiary. The newly announced #acquisition will bring JC Medical, Inc.’s J-valve transcatheter #aortic valve replacement (TAVR) system under Edward’s rapid growing portfolio which includes recent acquistions of Innovalve Bio Medical Ltd., JenaValve Technology, Inc., Endotronix, and significant investment into Affluent Medical. Edward’s has not yet disclosed financial details however this new deal adds to over $1.5B USD in M&A activity this year along and counting. “J-Valve has unique advantages in treating aortic valve regurgitation. We hope that J-Valve can expand its global impact, enabling more patients to benefit from this innovative product. We will continue strengthening our focus on developing innovative products and explore better medical solutions to benefit more patients worldwide." - Warren Wang, Chairman & CEO of Genesis Medtech Group #medtechmoney #mergersandacquisitions #structuralheart #medtechdeals The Mullings Group

Shockwave Medical: The Billion-Dollar Game Changer for J&J MedTech   Johnson & Johnson's Q2 earnings report highlights their acquisition of Shockwave Medical, set to add $500 million in sales by year-end. In just the first 30 days, Shockwave contributed $77 million, showcasing its immediate impact. Chalk, Borrowed from Shockwave’s website:  “In 2009, a marketer, engineer and cardiologist came together to change the nature of interventional therapy for calcified cardiovascular disease. They envisioned a future in which lithotripsy, a trusted technology used to break kidney stones for more than three decades, could be adapted to crack calcium in undilatable lesions in a potentially easier and safer manner. What started out as a crazy idea is now changing the standard of care for patients with calcified disease around the globe.” Have you ever seen a medical device’s revenue ramp up as fast? Share your experience in the comment below. “We closed that transaction in record timing, and we are really excited to shortly announce that they will be the 13th business with sales in excess of $1 billion annually,” added J&J MedTech’s worldwide chairman, Tim Schmid. Find more details in the article linked in the comments. #Biotechnology #HealthcareInnovation #MedTech #JohnsonAndJohnson #ShockwaveMedical #CardiovascularHealth #MedicalAdvancements #HealthcareTech #Innovation #LifeSciences 

✔️4C Medical Technologies, Inc. announced the FDA granted breakthrough device designation for its AltaValve system. The company received designations for two therapeutic indications for the transcatheter mitral valve replacement device. 👏Saravana Kumar, CEO and President commented: “This advancement enables us the opportunity to bring this needed technology to our patients even sooner.” 🔗Read more: https://lnkd.in/dJjiTFhJ 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dYC56Usw #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #Surgeons #GuidedSolutions

Once again, MicroPort tops Medical Design & Outsourcing’s Big 100 when it comes to the percentage of revenue spent on research & development (R&D). MicroPort spends 49.9% of its revenue on R&D. MicroPort ranks seventy-seventh overall on the Big 100. Highlighted in the article was MicroPort CRM’s FDA approval of the Alizea and Celea pacemakers. The Alizea and Celea pacemakers offer the greatest longevity available in a small-sized pacemaker generator (13 years; 11 cc). https://lnkd.in/gTn8rXfp

🚀 Irish medical device firm Ceroflo announced it has raised €6.4 million in investment-round funding, to help develop its SubMax device—a novel stent intended to “revolutionise” intracranial atherosclerotic disease treatments. 📣 CEO Chloe Brown commented: "We are approaching the problem with a unique understanding of the challenges and are designing the technology with clinicians who have more than 50 years’ collective experience treating this disease. [...] This €6.4 million investment will enable Ceroflo to bring the SubMax stent to 30 patients in a first-in-human trial—a significant value inflection point. It will also allow us to provide a platform to support further US and Japanese regulatory studies.” 👉 Read more: https://lnkd.in/di884E5J 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dJqiv63c #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #Surgeons #GuidedSolutions #Investment #FundingRound

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) recently used their OneRF ablation system at a top hospital in Jacksonville, USA, to perform five successful brain ablations on a single patient. 🧠 In this procedure, 10 Evo sEEG electrodes were implanted in the patient's brain. Four electrodes identified seizure-causing areas, and targeted ablations were conducted using the system’s temperature control feature. Two ablations occurred on different contacts of the same electrode. Post-ablation sEEG recordings confirmed the success by showing no brain activity in the ablated regions. The procedure was performed at the patient's bedside, avoiding the time and cost of using an operating room. "This marks an exciting milestone for us," said NeuroOne CEO Dave Rosa. "Performing safe ablations at the bedside reduces operating room use and costs, allowing for more procedures. We anticipate more uses of the OneRF system to monitor and treat problematic brain tissue. We plan to expand its applications with future FDA submissions." The OneRF ablation system is NeuroOne's first therapeutic device and third FDA 510(k)-cleared device. It launched commercially in March 2024 and recently received an ICD-10 procedure code from the US Centers for Medicare and Medicaid Services (CMS).

𝐌𝐞𝐝𝐭𝐫𝐨𝐧𝐢𝐜 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 (2011-2023)   Historically Medtronic reported its revenue with the following breakdown: 1- Cardiovascular 2- Restorative Therapies   The flowing are some of the highlights of #Medtronic over the years.   2011: Omar Ishrak becomes the new CEO and Chairman of Medtronic. During his time, he doubles Medtronic's revenue and valuation. 2013: Medtronic separates “Diabetes” from “Restorative Therapies” and turns it into a stand-alone division. 2014: Medtronic acquires Covidien (Medtronic Minimally Invasive Therapies Group) for $42.9B. After the acquisition, Medtronic adds “Minimally Invasive Therapies” to its revenue breakdown. Today Covidien accounts for roughly one-third of Medtronic's revenue. 2016: Medtronic becomes top #medicaldevice company by revenue. To this date, Medtronic maintains this position. 2020: Geoff Martha becomes the new CEO and Chairman of Medtronic. 2020: Medtronic changes its “Minimally Invasive Therapies” division to “Medical Surgical” and “Restorative Therapies” to “Neuroscience”.   Today Medtronic breaks down its revenue ($31.2B) into the following four divisions: 1. Cardiovascular ($11.6B), 2. Medical-Surgical ($8.4B), 3. Neuroscience ($9B) 4. Diabetes ($2.3B).   Over the last few years, Medtronic has shown steady growth in almost all its divisions. The acquisition of #Covidien has also proved to be very successful. In addition to the Top-line growth, Medtronic has also shown a steady increase in its bottom line, thanks to its strong economics. Today, Medtronic is the top medical device company by revenue followed by Johnson & Johnson MedTech and Siemens Healthineers.   The combination of having the highest revenue and high profit margin has made Medtronic one of the most valued medical companies. Today Medtronic has a market cap comparable to that of Siemens Healthineers, GE HealthCare, and Philips combined ($110B vs $65B + $40B + $20B). Would be interesting to see if Medtronic can maintain its top position in coming years.

Johnson & Johnson has announced its acquired Shockwave Medical. Under the terms of the deal, Johnson & Johnson will purchase all outstanding shares of Shockwave for $335.00 per share in cash, totaling approximately $13.1 billion including cash acquired. The transaction, approved by both companies' boards of directors, aims to bolster Johnson & Johnson's presence in cardiovascular intervention and tap into higher-growth markets. With this acquisition, Johnson & Johnson's medtech cardiovascular portfolio will expand into coronary artery disease (CAD) and peripheral artery disease (PAD). This move follows Johnson & Johnson MedTech's recent acquisitions of Abiomed, a heart recovery leader, and Laminar, specializing in left atrial appendage elimination for patients with non-valvular atrial fibrillation (AF). Shockwave Medical is recognized for its intravascular lithotripsy (IVL) technology, which treats calcified CAD and PAD through minimally invasive, catheter-based procedures, mitigating risks like reduced blood flow or heart attacks.